Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022.

ABSTRACT:

Background

Epidemiological data for United States (US) hospitals regarding the burden of Acinetobacter baumannii and carbapenem-resistant A. baumannii (CRAB) are scarce; thus, this study aimed to describe the incidence of A. baumannii and CRAB across US hospitals between January 1, 2018 and December 31, 2022.

Methods

This was a retrospective cohort study of hospitalized patients with microbiology data from the PINC AI™ Database. Incidence rates of A. baumannii and CRAB (January 1, 2018 - December 31, 2022) were determined across US hospitals in each census region. Incidence rates of A. baumannii and CRAB were determined at the hospitalization encounter and individual levels. Presence of CRAB was based on non-susceptibility to either doripenem, imipenem, or meropenem. Patient

SUBMITTER: Lodise TP 

PROVIDER: S-EPMC12004818 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature